tripartite motif containing 37Genealiases: MUL · POB1 · TEF3
Q-omics provides the consensus-scored TRIM37 profile across patient tissues and cancer cell-line models. TRIM37 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRIM37 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TRIM37 RNA expression shows 21,374 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where TRIM37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM37 survival associations across molecular data types. TRIM37 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM37 RNA expression–survival associations across cancer types. High TRIM37 expression shows unfavorable associations in ACC, LIHC, KIRP, BLCA, KICH and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRIM37 RNA expression.
This table summarizes TRIM37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRIM37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM37 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, KIRP, LIHC and LUAD. The HNSC box plot shows higher TRIM37 RNA expression in tumor versus normal tissue (log2 FC = +0.908, t-test p < 0.001).
This table shows molecular features associated with TRIM37 in patient tissues and cancer cell lines. In patient samples, TRIM37 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
